Georgetown’s Sabrina Corlette explains some of the motivations behind the spate of premium credits and discounts from health insurers in this part one of two series.
A steady stream of health insurers have announced premium credits and discounts in recent weeks and months after their profits (net income, for not-for-profits) have swelled because of the drop-off in routine healthcare utilization.
In an video interview with Managed Healthcare Executive® this week, Sabrina Corlette, J.D., discussed some of the possible motivations behind the largess.
“Here in Washington, in the halls of Congress, and in state Capitols, I think insurers are well aware that legislators and policymakers know that they have had a very good year,” said Corlette, one of the country’s foremost experts on health insurance and founder and co-director of the Center on Health Insurance Reforms at Georgetown University’s McCourt School of Public Policy.
With policymakers looking for places to find funds, health insurers know “they might have a target on their back,” add Corlette. “I think to the extent that they can generate some good will and some good public relations by offering premium holidays and premium discounts, that is helpful to them.”
Another factor may be their medical-loss ratios (MLRs) — the share of the premium dollar that is supposed to be spent on healthcare. The ACA set the MLR for insurance sold in the individual and small group markets at 80% and for insurance sold to large employers, at 85%. With the decline in healthcare utilization, many insurers are well under their MLRs. If they stay under, they will be required to pay MLR rebates.
Corlette explained that if companies can boost their MLR by getting a bit less in premium revenue, that means less that they will have to pay back later in MLR rebates.
“I think a lot of carriers are thinking, ‘We are going to owe this money back to the policyholders anyway’ and right now people are suffering – people maybe have lost their jobs or lost income.”
Medicaid Cuts Remain Center Stage as Experts Address Industry Challenges
March 28th 2025In a recent conversation with Jennifer McGuigan Babcock, senior vice president for Medicaid policy at the Association for Community Affiliated Plans (ACAP), and Gabe Scott, a partner at K&L Gates Health Care Group, the two discussed efforts to protect Medicaid’s role in the healthcare system and the consequences of the budget cuts announced in February.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
Medicaid Cuts Remain Center Stage as Experts Address Industry Challenges
March 28th 2025In a recent conversation with Jennifer McGuigan Babcock, senior vice president for Medicaid policy at the Association for Community Affiliated Plans (ACAP), and Gabe Scott, a partner at K&L Gates Health Care Group, the two discussed efforts to protect Medicaid’s role in the healthcare system and the consequences of the budget cuts announced in February.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
2 Commerce Drive
Cranbury, NJ 08512